ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and … – Business Wire (press release)
|
ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and …
Business Wire (press release) DUBLIN & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–ERS Genomics Ltd. and Cellecta, Inc. announced today a non-exclusive license agreement to provide Cellecta with worldwide access to ERS Genomics' CRISPR/Cas9 genome editing intellectual … |
